Search Result
Results for "
serotonin release
" in MedChemExpress (MCE) Product Catalog:
2
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-172420
-
|
GM-2505
|
5-HT Receptor
|
Neurological Disease
|
|
Bretisilocin (GM-2505) is the agonist for 5-HT2A receptor and a serotonin releaser. Bretisilocin exhibits antidepressant activity and can be used in the study of depression .
|
-
-
- HY-100656
-
|
|
Dopamine Receptor
5-HT Receptor
|
Neurological Disease
|
|
Desmethyl cariprazine is a major active metabolite of cariprazine, with activities at human dopamine receptors and serotonin receptors, showing a pEC50 of 8.90 at human D2 receptors, a pEC50 of 8.09 at D3 receptors, and a pEC50 of 6.28 at 5-HT1A receptors. Desmethyl cariprazine inhibits forskolin-induced cAMP production at D2, D3 and 5-HT1A receptors, and suppresses serotonin-induced Ca 2+ release at 5-HT2B receptors. Desmethyl cariprazine is applicable to research related to schizophrenia, bipolar disorder type I and bipolar disorder.
|
-
-
- HY-B1693
-
|
Methotrimeprazine
|
5-HT Receptor
Dopamine Receptor
Histamine Receptor
Autophagy
Enterovirus
Calcium Channel
|
Infection
Neurological Disease
Inflammation/Immunology
|
|
Levomepromazine (Methotrimeprazine) is an orally active antipsychotic compound and Ca 2+ release inducer. Levomepromazine inhibits SERCA pump and induces an increase in cytoplasmic Ca 2+ levels. Levomepromazine has antagonistic effects on a variety of neurotransmitter receptors, including dopamine, cholinergic, serotonin, and histamine receptors. Levomepromazine can induce adaptive ER stress and autophagy. In addition, Levomepromazine has antiviral, anti-inflammatory, neuroprotective and analgesic, sedative and anti-injurious activities. Levomepromazine can be used in the study psychiatric disorders and relieving nausea and vomiting .
|
-
-
- HY-N7097
-
|
|
Antibiotic
Bacterial
|
Infection
|
|
Sulbenicillin disodium is a semisynthetic α-sulfonylbenzylpenicillin antibiotic. Sulbenicillin disodium exerts antibacterial activity against multiple gram-negative rods. Sulbenicillin disodium inhibits primary and secondary platelet aggregation, serotonin release from platelets, and platelet adherence via platelet surface coating. Sulbenicillin disodium can be used for the research of Pseudomonas aeruginosa, Pseudomonas maltophilia, and Pseudomonas cepacia infections .
|
-
-
- HY-D2335
-
|
|
Fluorescent Dye
|
Neurological Disease
|
|
SERTlight is a fluorescent agent that can specifically label serotonergic neuronal cell bodies, dendrites, and axonal projections as fluorescent substrates of the serotonin transporter (SERT). SERTlight is orthogonal to various genetically encoded sensors in terms of optics, pharmacology, and operation, enabling multiple imaging. SERTlight allows the use of GRAB5HT sensors to label distal 5HT axonal projections and simultaneously image the release of endogenous 5HT, providing a new multifunctional molecular tool for studying serotonergic systems .
|
-
-
- HY-W100249
-
-
-
- HY-106865
-
|
|
Dopamine Receptor
Adrenergic Receptor
|
Cardiovascular Disease
|
|
Mivazerol is a selective α2-adrenoceptor agonist. Mivazerol decreases the spontaneous release of serotonin (5-HT) and significantly inhibits the immobilization stress-induced enhancement of norepinephrine (NE), dopamine (DA) and dihydroxyphenylacetic acid (DOPAC). Mivazerol inhibits intrathecal release of glutamate evoked by halothane withdrawal in rats, and exerts neuroprotective effects in forebrain ischemia rats. Mivazerol can be used for myocardial ischemia research .
|
-
-
- HY-103465
-
|
|
Monoamine Transporter
|
Others
|
|
FFN511 is a potent fluorescent false neurotransmitters (FFNs) that targets neuronal vesicular monoamine transporter 2 (VMA T2). FFN511 inhibits serotonin binding to VMA T2-containing membranes with an IC50 of 1 µM. FFN511 directly images the dynamics of release during exocytosis, can be used to label dopamine terminals in live cortical-striatalacute slices .
|
-
-
- HY-18332C
-
|
|
Serotonin Transporter
Dopamine Transporter
|
Neurological Disease
|
|
DOV-216,303 (Free Base) is a potent triple serotonin, norepinephrine, and dopamine reuptake inhibitor, with IC50 values of 14 nM, 20 nM and 78 nM for hSERT, hNET and hDAT, respectively. Has antidepressant-like effects and increases monoamine release in the prefrontal cortex of olfactory bulbectomized (OBX) rats .
|
-
-
- HY-156807
-
|
|
Serotonin Transporter
5-HT Receptor
|
Neurological Disease
|
LY 367265 is a 5-hydroxytryptamine transporter (SERT) inhibitor (IC₅₀ = 3.1 nM) and a 5-HT₂A receptor antagonist (Kᵢ = 0.81 nM). LY 367265 has the inhibitory activity on the norepinephrine transporter (NET) of extremely weak (IC₅₀ > 1000 nM); it has low affinity for subtypes such as 5-HT₁B (Kᵢ = 490 nM) and 5-HT₁D (Kᵢ = 81 nM), showing high selectivity. LY 367265 concentration-dependently enhances of [³H]5-HT efflux (EC₅₀ = 250 nM). LY 367265 antagonizes the contraction response of Sumatriptan (HY-B0121B), indicating its functional antagonistic activity on 5-HT₁D-like receptors. LY 367265 can be used for the study of diseases such as anxiety disorders and post-traumatic stress disorder .
|
-
-
- HY-172071
-
|
PAL-1046 hydrochloride
|
5-HT Receptor
|
Neurological Disease
|
|
Methamnetamine (PAL-1046) hydrochloride is an amphetamine-based psychoactive substance. Methamnetamine hydrochloride causes excessive release of serotonin .
|
-
-
- HY-127023
-
|
EPA-5-HT
|
Endogenous Metabolite
FAAH
Interleukin Related
Tyrosine Hydroxylase
|
Metabolic Disease
|
|
Eicosapentaenoyl serotonin (EPA-5-HT) is an endogenous fatty acid-serotonin conjugate lipid mediator. Eicosapentaenoyl serotonin acts as an inhibitor of fatty acid amide hydrolase (FAAH). Eicosapentaenoyl serotonin suppresses IL-17 release in Concanavalin A (HY-P2149)-stimulated human peripheral blood mononuclear cells. Eicosapentaenoyl serotonin is regulated by polyunsaturated fatty acids and modulates intestinal immunity and Th17 signaling. Eicosapentaenoyl serotonin can be used for the study of inflammatory bowel disease-related mechanisms .
|
-
-
- HY-116680
-
|
|
5-HT Receptor
|
Cardiovascular Disease
Neurological Disease
|
|
LY53857 is a potent antagonist of vasoconstriction and serotonin-mediated 5-HT2 receptors. LY53857 did not reduce mean arterial blood pressure in spontaneously hypertensive rats (SHR) at doses that blocked the depressor response to serotonin and blocked central serotonin receptors. In addition, LY53857 was able to enhance neurotransmitter release in rat vas deferens and guinea pig ileal nerves .
|
-
-
- HY-19125
-
-
-
- HY-120155
-
|
|
Sigma Receptor
iGluR
|
Neurological Disease
|
|
MS-377 is a selective and orally active sigma-1 receptor ligand (Ki=73 nM) with weak affinity for sigma-2 receptor (Ki=6900 nM) and no affinity for any other receptors including dopamine, serotonin, PCP site, glutamate, γ-aminobutylic acid, adenosine, adrenergic receptors, etc. (Ki: >10 μM). MS-377 indirectly modulates the NMDA receptor ion-channel complex. MS-377 is a antipsychotic agent. MS-377 inhibits PCP-induced behaviors by inhibition of the increase in dopamine and serotonin release in the rat medial prefrontal cortex. MS-377 can be used for research of schizophrenia .
|
-
-
- HY-B1693A
-
|
Methotrimeprazine hydrochloride
|
5-HT Receptor
Dopamine Receptor
Histamine Receptor
Autophagy
Enterovirus
Calcium Channel
|
Infection
Neurological Disease
Inflammation/Immunology
|
|
Levomepromazine (Methotrimeprazine) hydrochloride is an orally active antipsychotic compound and Ca 2+ release inducer. Levomepromazine inhibits SERCA pump and induces an increase in cytoplasmic Ca 2+ levels. Levomepromazine hydrochloride has antagonistic effects on a variety of neurotransmitter receptors, including dopamine, cholinergic, serotonin, and histamine receptors. Levomepromazine hydrochloride can induce adaptive ER stress and autophagy. In addition, Levomepromazine hydrochloride has antiviral, anti-inflammatory, neuroprotective and analgesic, sedative and anti-injurious activities. Levomepromazine hydrochloride can be used in the study psychiatric disorders and relieving nausea and vomiting .
|
-
-
- HY-B1693R
-
|
Methotrimeprazine (Standard)
|
Reference Standards
5-HT Receptor
Dopamine Receptor
Autophagy
Histamine Receptor
Enterovirus
Calcium Channel
|
Infection
Neurological Disease
Inflammation/Immunology
|
|
Levomepromazine (Standard) is the analytical standard of Levomepromazine. This product is intended for research and analytical applications. Levomepromazine (Methotrimeprazine) is an orally active antipsychotic compound and Ca 2+ release inducer. Levomepromazine inhibits SERCA pump and induces an increase in cytoplasmic Ca 2+ levels. Levomepromazine has antagonistic effects on a variety of neurotransmitter receptors, including dopamine, cholinergic, serotonin, and histamine receptors. Levomepromazine can induce adaptive ER stress and autophagy. In addition, Levomepromazine has antiviral, anti-inflammatory, neuroprotective and analgesic, sedative and anti-injurious activities. Levomepromazine can be used in the study psychiatric disorders and relieving nausea and vomiting .
|
-
-
- HY-175721
-
|
|
Serotonin Transporter
|
Neurological Disease
|
|
UCD0820 is a Serotonin transporter (SERT) inhibitor that acts as a partial serotonin releasing agent (SRA). UCD0820 can be used for depression, addiction and post-traumatic stress disorder (PTSD) research .
|
-
-
- HY-175720
-
|
|
Serotonin Transporter
|
Neurological Disease
|
|
UCD0168 is a Serotonin transporter (SERT) inhibitor that acts as a full serotonin releasing agent (SRA). UCD0168 can be used for depression, addiction and post-traumatic stress disorder (PTSD) research .
|
-
-
- HY-W158945
-
-
-
- HY-W342779
-
|
|
Dopamine Receptor
|
Neurological Disease
|
|
4-Bromoamphetamine hydrochloride is an amphetamine derivative which acts as a serotonin-norepinephrine-dopamine releasing agent (SNDRA) and produces stimulant effects. 4-Bromoamphetamine hydrochloride is highly neurotoxic, producing long-term depletion of serotonin .
|
-
-
- HY-131556
-
|
p-Iodoamphetamine hydrochloride
|
5-HT Receptor
|
Neurological Disease
|
|
4-Iodoamphetamine (p-Iodoamphetamine) hydrochloride is a halogenated amphetamine featuring an iodine atom at the para position of the phenyl group. 4-Iodoamphetamine hydrochloride selectively induces serotonin release and inhibits reuptake by rat brain synaptosomes.
|
-
-
- HY-162511
-
|
|
Dopamine Transporter
Serotonin Transporter
|
Others
|
|
IP2015 is an inhibitor for monoamine reuptake, that inhibits the reuptake of dopamine, serotonin (5-HT), and noradrenaline. IP2015 increases release of central dopamine and peripheral nitric oxide (NO), causes the NO-mediated relaxation of erectile tissue, and thus induces erection in rat model .
|
-
-
- HY-135222
-
|
5-Methoxy-6-methyl-2-aminoindan hydrochloride
|
5-HT Receptor
|
Neurological Disease
|
|
MMAI (5-Methoxy-6-methyl-2-aminoindan) hydrochloride is a selective serotonin releaser that does not produce psychoactive or hallucinogenic effects in the context of drug discrimination in rats. MMAI hydrochloride induces a behavioral syndrome in rats, including hypokinesia with freezing, spinning, Straub tail, flat posture, and reduced sleep time .
|
-
-
- HY-W061043
-
|
|
Serotonin Transporter
Dopamine Transporter
|
Neurological Disease
|
|
DOV-216,303 is an antidepressant compound. DOV-216,303 inhibits the reuptake of norepinephrine (NE), serotonin (5‐HT), and dopamine (DA), with IC50 values of 14 nM, 20 nM and 78 nM for hSERT, hNET and hDAT, respectively. DOV-216,303 increases monoamine release in the prefrontal cortex of olfactory bulbectomized (OBX) rats .
|
-
-
- HY-133858
-
|
|
5-HT Receptor
|
Neurological Disease
|
|
25N-NBOMe hydrochloride, a 2C-N derivative, is a 5-HT2A and 5-HT2C receptors agonist with Ki values of 0.144 nM and 1.06 nM, respectively. 25N-NBOMe hydrochloride has little to no efficacy at inducing release of preloaded neurotransmitter from recombinant dopamine, serotonin and norepinephrine transporters .
|
-
-
- HY-111066
-
|
|
Dopamine Receptor
|
Others
|
|
JNJ-37822681 is a fast dissociating D2 antagonist with activity in inhibiting schizophrenia. JNJ-37822681 has high specificity for D2 receptors and is effective in animal models, inducing increased levels of extracellular serotonin, dopamine, and norepinephrine in the rat cerebral cortex, and exhibiting antidepressant activity in the mouse tail suspension test, while having a good brain distribution and lower prolactin release.
|
-
-
- HY-103465B
-
|
|
Monoamine Transporter
|
Others
|
|
FFN511 (hydrochloride) is a potent fluorescent false neurotransmitters (FFNs) that targets neuronal vesicular monoamine transporter 2 (VMA T2). FFN511 (hydrochloride) inhibits serotonin binding to VMA T2-containing membranes with an IC50 of 1 µM. FFN511 (hydrochloride) directly images the dynamics of release during exocytosis, can be used to label dopamine terminals in live cortical-striatalacute slices .
|
-
-
- HY-116778
-
|
|
Reactive Oxygen Species (ROS)
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
|
Prostaglandin G2 is a prostaglandin peroxide. Prostaglandin G2 acts as a precursor for thromboxane A2 production, inducing platelet aggregation and serotonin release. Prostaglandin G2 also induces cerebral arteriole injury in anesthetized cats via the generation of reactive oxygen free radicals, triggering persistent vasodilation, reduced reactivity to hypocapnia, and endothelial damage. Prostaglandin G2 can be used in studies related to cerebral arteriole injury .
|
-
-
- HY-174146
-
|
|
5-HT Receptor
|
Neurological Disease
|
|
5-HT1A agonist 1 (Compound Ex.37) is a highly selective 5-HT1a receptor agonist (EC50=0.18 nM). 5-HT1A agonist 1 mimicks serotonin binding to the receptor, promotes postsynaptic membrane hyperpolarization, inhibits neuronal hyperexcitability, and reduces the release of anxiety-related neurotransmitters. 5-HT1A agonist 1 is promising for research of neuropsychiatric diseases .
|
-
-
- HY-141554A
-
|
(2S,3S,11bR)-DHTBZ
|
Monoamine Transporter
|
Neurological Disease
|
|
(2S,3S,11bR)-Dihydrotetrabenazine ((2S,3S,11bR)-DHTBZ) is a highly selective inhibitor of vesicular monoamine transporter 2 (VMAT2) with a Ki value of 593 nM. (2S,3S,11bR)-Dihydrotetrabenazine inhibits vesicular transport of monoamine neurotransmitters like dopamine and serotonin, reducing their synaptic release. (2S,3S,11bR)-Dihydrotetrabenazine is promising for research of Huntington's chorea and other hyperkinetic disorders .
|
-
-
- HY-111136
-
|
|
GABA Receptor
5-HT Receptor
Dopamine Receptor
Histamine Receptor
|
Neurological Disease
|
|
BL-1020 mesylate is the mesylate salt form of BL-1020. BL-1020 mesylate is an antipsychotic agent. BL-1020 mesylate is inhibitor for dopamine receptor and serotonin receptor (5-HT receptor), with Ki of 0.066, 0.062 and 0.21 nM, for D2L, D2S and 5-HT2A receptors, respectively. BL-1020 mesylate is agonist for GABAA receptor with Ki of 3.74 μM, and enhances the GABA release. BL-1020 mesylate exhibits high affinity with histamine receptor (Ki is 0.47 nM). BL-1020 mesylate reduces Amphetamine-induced hyperactivity, with lower catalepsy and sedation. BL-1020 mesylate is blood-brain barrier penetrate .
|
-
-
- HY-165395
-
|
|
Phosphodiesterase (PDE)
|
Inflammation/Immunology
|
|
AY 25674 is an orally active antiallergic agent and a PDE inhibitor. AY 25674 inhibits the release of allergic histamine from mast cells. AY 25674 suppresses passive anaphylaxis induced by reaginic (IgE) antibodies. AY 25674 does not inhibit the increased vascular permeability caused by non-reaginic antibodies, serotonin or histamine. AY 25674 reaches its peak activity shortly after administration; rapid tolerance occurs at high doses. AY 25674 can be used in research related to passive anaphylaxis .
|
-
-
- HY-186169A
-
-
-
- HY-186169B
-
-
-
- HY-172763
-
|
|
Drug Derivative
Serotonin Transporter
Dopamine Transporter
5-HT Receptor
|
Neurological Disease
|
|
EDMA hydrochloride is a derivative of MDMA. EDMA hydrochloride is a substrate for multiple neurotransmitter transporters, including serotonin transporter (SERT), dopamine transporter (DAT), and norepinephrine transporter (NET). EDMA hydrochloride has 5-HT releasing activity at SERT (EC50 = 117 nM) and MPP + releasing activity at DAT (EC50 = 597 nM) and NET (EC50 = 325 nM) .
|
-
-
- HY-100656AS
-
|
|
Isotope-Labeled Compounds
Dopamine Receptor
5-HT Receptor
|
Neurological Disease
|
|
Desmethyl cariprazine-d8 is the deuterium labeled Desmethyl cariprazine (HY-100656). Desmethyl cariprazine is a major active metabolite of cariprazine, with activities at human dopamine receptors and serotonin receptors, showing a pEC50 of 8.90 at human D2 receptors, a pEC50 of 8.09 at D3 receptors, and a pEC50 of 6.28 at 5-HT1A receptors. Desmethyl cariprazine inhibits forskolin-induced cAMP production at D2, D3 and 5-HT1A receptors, and suppresses serotonin-induced Ca 2+ release at 5-HT2B receptors. Desmethyl cariprazine is applicable to research related to schizophrenia, bipolar disorder type I and bipolar disorder.
|
-
-
- HY-103465R
-
|
|
Reference Standards
Monoamine Transporter
|
Others
|
|
FFN511 (Standard) is the analytical standard of FFN511 (HY-103465). This product is intended for research and analytical applications. FFN511 is a potent fluorescent false neurotransmitters (FFNs) that targets neuronal vesicular monoamine transporter 2 (VMA T2). FFN511 inhibits serotonin binding to VMA T2-containing membranes with an IC50 of 1 μM. FFN511 directly images the dynamics of release during exocytosis, can be used to label dopamine terminals in live cortical-striatalacute slices .
|
-
-
- HY-166562S
-
|
Methotrimeprazine-d6 hydrochloride
|
Isotope-Labeled Compounds
Enterovirus
Histamine Receptor
Autophagy
5-HT Receptor
Calcium Channel
Dopamine Receptor
|
Infection
Neurological Disease
Inflammation/Immunology
|
|
Levomepromazine-d6 hydrochloride (Methotrimeprazine-d6 hydrochloride) is the deuterium labeled Levomepromazine hydrochloride. Levomepromazine (Methotrimeprazine) hydrochloride is an orally active antipsychotic compound and Ca 2+ release inducer. Levomepromazine inhibits SERCA pump and induces an increase in cytoplasmic Ca 2+ levels. Levomepromazine hydrochloride has antagonistic effects on a variety of neurotransmitter receptors, including dopamine, cholinergic, serotonin, and histamine receptors. Levomepromazine hydrochloride can induce adaptive ER stress and autophagy. In addition, Levomepromazine hydrochloride has antiviral, anti-inflammatory, neuroprotective and analgesic, sedative and anti-injurious activities. Levomepromazine hydrochloride can be used in the study psychiatric disorders and relieving nausea and vomiting .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-D2335
-
|
|
Fluorescent Dyes
|
|
SERTlight is a fluorescent agent that can specifically label serotonergic neuronal cell bodies, dendrites, and axonal projections as fluorescent substrates of the serotonin transporter (SERT). SERTlight is orthogonal to various genetically encoded sensors in terms of optics, pharmacology, and operation, enabling multiple imaging. SERTlight allows the use of GRAB5HT sensors to label distal 5HT axonal projections and simultaneously image the release of endogenous 5HT, providing a new multifunctional molecular tool for studying serotonergic systems .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-N7097
-
|
|
Infection
Classification of Application Fields
Disease Research Fields
|
Antibiotic
Bacterial
|
|
Sulbenicillin disodium is a semisynthetic α-sulfonylbenzylpenicillin antibiotic. Sulbenicillin disodium exerts antibacterial activity against multiple gram-negative rods. Sulbenicillin disodium inhibits primary and secondary platelet aggregation, serotonin release from platelets, and platelet adherence via platelet surface coating. Sulbenicillin disodium can be used for the research of Pseudomonas aeruginosa, Pseudomonas maltophilia, and Pseudomonas cepacia infections .
|
-
-
- HY-116778
-
|
|
Source Classification
|
Reactive Oxygen Species (ROS)
|
|
Prostaglandin G2 is a prostaglandin peroxide. Prostaglandin G2 acts as a precursor for thromboxane A2 production, inducing platelet aggregation and serotonin release. Prostaglandin G2 also induces cerebral arteriole injury in anesthetized cats via the generation of reactive oxygen free radicals, triggering persistent vasodilation, reduced reactivity to hypocapnia, and endothelial damage. Prostaglandin G2 can be used in studies related to cerebral arteriole injury .
|
-
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-100656AS
-
|
|
|
Desmethyl cariprazine-d8 is the deuterium labeled Desmethyl cariprazine (HY-100656). Desmethyl cariprazine is a major active metabolite of cariprazine, with activities at human dopamine receptors and serotonin receptors, showing a pEC50 of 8.90 at human D2 receptors, a pEC50 of 8.09 at D3 receptors, and a pEC50 of 6.28 at 5-HT1A receptors. Desmethyl cariprazine inhibits forskolin-induced cAMP production at D2, D3 and 5-HT1A receptors, and suppresses serotonin-induced Ca 2+ release at 5-HT2B receptors. Desmethyl cariprazine is applicable to research related to schizophrenia, bipolar disorder type I and bipolar disorder.
|
-
-
- HY-166562S
-
|
|
|
Levomepromazine-d6 hydrochloride (Methotrimeprazine-d6 hydrochloride) is the deuterium labeled Levomepromazine hydrochloride. Levomepromazine (Methotrimeprazine) hydrochloride is an orally active antipsychotic compound and Ca 2+ release inducer. Levomepromazine inhibits SERCA pump and induces an increase in cytoplasmic Ca 2+ levels. Levomepromazine hydrochloride has antagonistic effects on a variety of neurotransmitter receptors, including dopamine, cholinergic, serotonin, and histamine receptors. Levomepromazine hydrochloride can induce adaptive ER stress and autophagy. In addition, Levomepromazine hydrochloride has antiviral, anti-inflammatory, neuroprotective and analgesic, sedative and anti-injurious activities. Levomepromazine hydrochloride can be used in the study psychiatric disorders and relieving nausea and vomiting .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: